GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bionomics Limited
Bionomics is an Australian biotech company developing drugs for the treatment of anxiety disorders and PTSD. Its stock price is volatile and dependent on the results of clinical trials.
Share prices of companies in the market segment - Pharma neurology
Bionomics is an Australian biopharmaceutical company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. We've categorized it as a Pharmaceutical: Neuroscience company. The chart below shows the dynamics of the mental health sector.
Broad Market Index - GURU.Markets
Bionomics is an Australian biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders. As a component of the GURU.Markets index, it represents the neuroscience sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
BNOX - Daily change in the company's share price Bionomics Limited
Bionomics Limited's daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its anxiety disorder treatments.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Bionomics is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Bionomics is an Australian biotech company developing drugs for the treatment of neurological diseases. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bionomics Limited
For Bionomics Limited, an Australian biotech, the year-to-date performance is a story about the development of its drugs for the treatment of anxiety and PTSD. Its 12-month market cap is entirely dependent on clinical trial data. The partnership with Merck is a key validation of the potential of its unique scientific approach.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Bionomics is a late-stage Australian biotech company developing drugs for the treatment of central nervous system diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bionomics, an Australian biopharmaceutical company developing drugs for anxiety disorders and PTSD, is working to address a pressing mental health issue. Its year-over-year market capitalization reflects the progress of its clinical trials and the potential of its drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bionomics Limited
Bionomics is an Australian biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its anxiety drug is generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders, such as anxiety disorders. The psychiatric pharmaceutical sector is vast. The chart below shows how investors assessed the prospects of new approaches to treating mental disorders.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bionomics is an Australian biotech company developing drugs for the treatment of central nervous system disorders. Its stock price is driven by clinical trial results and is independent of the US market, adding an element of geographic diversification to its risk profile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bionomics Limited
Shares of Bionomics, an Australian biopharmaceutical company developing drugs for the treatment of central nervous system disorders, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials. The chart below illustrates how short-term scientific developments and investor expectations in this complex field influence the stock.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat anxiety disorders and PTSD. Mental health is a huge market. The chart shows how news about clinical trials affects the company's stock, creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bionomics is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
BNOX - Market capitalization of the company Bionomics Limited
Bionomics Limited's market capitalization reflects its developments in the treatment of anxiety disorders and PTSD. The valuation of this Australian biotech company, backed by major investors, reflects its hopes for the development of a new class of drugs for these common conditions.
BNOX - Share of the company's market capitalization Bionomics Limited within the market segment - Pharma neurology
Bionomics's market share reflects its focus on treating anxiety disorders and PTSD. Its market share is based on the potential of its lead drug candidate, which targets a new mechanism in the brain and could become a breakthrough treatment for millions of patients.
Market capitalization of the market segment - Pharma neurology
Here's a chart of the total market capitalization of biotech companies developing drugs for the treatment of central nervous system diseases. Bionomics is one such player. The chart's dynamics reflect the high volatility and risks associated with clinical trials in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of anxiety treatments. The market capitalization of Bionomics Limited, an Australian company, is based on the valuation of its drugs targeting new mechanisms in the brain. The line shows how science is struggling to find its share of the vast and complex mental health treatment market.
Book value capitalization of the company, segment and market as a whole
BNOX - Book value capitalization of the company Bionomics Limited
The chart below shows the scientific foundation of Bionomics Limited. Its line reflects the value of intellectual property for drugs used to treat anxiety disorders and PTSD. The dynamics reflect the company's clinical research activity, which is its main asset.
BNOX - Share of the company's book capitalization Bionomics Limited within the market segment - Pharma neurology
Bionomics' tangible assets include its R&D laboratories developing drugs for anxiety disorders and PTSD. The chart shows the company's share of this scientific infrastructure, which serves as the physical basis for its innovative psychiatric programs.
Market segment balance sheet capitalization - Pharma neurology
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Bionomics, as a development company, has a more streamlined model. Its value lies in its intellectual property rights to drugs for treating central nervous system diseases, not in its scale of production.
Book value of all companies included in the broad market index - GURU.Markets
Bionomics is an Australian biotech company developing drugs for the treatment of anxiety disorders and PTSD. Its assets include a patent portfolio and clinical trial data targeting complex brain diseases. The chart shows the financial resources devoted to "calm chemistry."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bionomics Limited
Bionomics is an Australian biotech company developing drugs to treat diseases of the central nervous system. Its assets are intangible. The chart below is a barometer of hope. Its movements will reflect news about clinical trials, which determine the company's future.
Market to book capitalization ratio in a market segment - Pharma neurology
Bionomics Limited is an Australian biotechnology company developing drugs to treat diseases of the central nervous system. Its value depends on the success of its clinical programs. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Bionomics is an Australian biopharmaceutical company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. This chart shows how the market views their lead candidate and its potential in this massive market.
Debts of the company, segment and market as a whole
BNOX - Company debts Bionomics Limited
Bionomics, an Australian biotech focused on CNS diseases, is using raised capital to conduct its late-stage clinical trials. This chart shows how the company is funding the development of its anxiety disorder drug, a costly and high-risk process.
Market segment debts - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. This chart shows how its debt policy reflects its need to fund expensive clinical trials in this complex area of medicine to bring its products to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bionomics Limited
Brookfield Reinsurance is a reinsurance company within the Brookfield ecosystem. Reinsurance is a capital-intensive business. The chart provides insight into its financial structure and the use of leverage to support its insurance liabilities and investment activities.
Market segment debt to market segment book capitalization - Pharma neurology
Bionomics is an Australian clinical-stage biotech company developing drugs to treat central nervous system disorders, such as anxiety disorders. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company funds its research.
Debt to book value of all companies in the market
Bionomics Limited is an Australian biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders. Psychiatry is a complex area for R&D. This chart of total market debt provides insight into the availability of capital to fund lengthy and risky clinical trials.
P/E of the company, segment and market as a whole
P/E - Bionomics Limited
For Bionomics, an Australian biotech company focused on neuroscience, the P/E ratio is irrelevant. It has no consistent profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' confidence in the success of its clinical trials.
P/E of the market segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders, particularly anxiety disorders and post-traumatic stress disorder (PTSD). This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies working to address complex mental health issues.
P/E of the market as a whole
Bionomics is an Australian biopharmaceutical company developing drugs to treat central nervous system disorders, particularly anxiety disorders and post-traumatic stress disorder. This risk appetite chart helps understand how investors value biotech companies working in the mental health field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bionomics Limited
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders, particularly anxiety disorders. This chart reflects market expectations for the success of its clinical programs. Future revenue depends on trial results.
%20P%2FE%20Bionomics%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bionomics-Limited&v=1772610972938 "Chart of the company's future (projected) P/E Bionomics Limited")
Future (projected) P/E of the market segment - Pharma neurology
Bionomics Limited is an Australian biotech company developing drugs for the treatment of anxiety disorders and PTSD. This chart reflects how the market views its clinical programs. It compares expectations for Bionomics with other companies working in the complex field of psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772610972958 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Bionomics is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders such as anxiety and PTSD. Its future depends on trial results. This graph, reflecting market optimism, influences investor willingness to fund long-term and risky projects in the complex field of psychiatry.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772610972970 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bionomics Limited
Bionomics is a clinical-stage biopharmaceutical company developing drugs to treat central nervous system disorders such as anxiety and post-traumatic stress disorder. Its financial performance is driven by R&D expenditures. This chart shows the investment required to address complex mental health issues.
Profit of companies in the market segment - Pharma neurology
Bionomics Limited is an Australian biotechnology company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. This graph, showing overall sector profitability, reflects the enormous need for new treatments for mental illnesses. Bionomics' success could have a significant impact on the entire industry.
Overall market profit
Bionomics is an Australian biotechnology company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders and PTSD. The company aims to address complex mental health issues.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bionomics Limited
Bionomics is an Australian biopharmaceutical company developing drugs for the treatment of anxiety disorders and PTSD. Future revenue projections are speculative and depend on the results of clinical trials.
%20profit%20of%20the%20company%20Bionomics%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bionomics-Limited&v=1772610973054 "Graph of future (projected) profit of the company Bionomics Limited")
Future (predicted) profit of companies in the market segment - Pharma neurology
Bionomics is a biopharmaceutical company developing new drugs to treat central nervous system disorders, including anxiety disorders and PTSD. This chart shows overall revenue forecasts for the neuroscience segment. It reflects analysts' expectations for breakthroughs in mental health treatments and how Bionomics might fit into them.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772610973058 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Bionomics is a biopharmaceutical company developing drugs to treat diseases of the central nervous system. Its success depends on the results of clinical trials. This chart, reflecting market sentiment, is important for Bionomics. During periods of optimism, investors are more inclined to fund long-term and risky projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772610973097 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bionomics Limited
Bionomics Limited is a clinical-stage biopharmaceutical company developing drugs for anxiety disorders and PTSD. This chart, which correlates market capitalization with missing revenue, is a measure of hope. It shows how investors view the potential of its lead drug to address the enormous need for new treatments for mental illness.
P/S market segment - Pharma neurology
Bionomics Limited is a biopharmaceutical company developing new treatments for central nervous system disorders, such as anxiety and post-traumatic stress disorder. This chart shows how investors value revenue in the neuroscience sector, demonstrating the level of expectations for Bionomics' clinical development and scientific potential.
P/S of the market as a whole
Bionomics Limited is an Australian clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders and post-traumatic stress disorder. This chart helps understand how the market values companies operating in the complex field of psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bionomics Limited
Bionomics is a clinical-stage biotech company developing drugs to treat diseases of the central nervous system. This chart shows the market's estimate of its potential future revenue. It reflects investor confidence in the success of its clinical programs, particularly in the treatment of anxiety disorders.
%20P%2FS%20Bionomics%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bionomics-Limited&v=1772610973153 "The graph of the company's future (projected) P/S Bionomics Limited")
Future (projected) P/S of the market segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. The chart shows the average future sales estimate for the neuroscience sector. It helps understand how investors view Bionomics' clinical development in this challenging area.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772610973189 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Bionomics (BNOX) is an Australian biotech company developing drugs to treat central nervous system disorders such as anxiety and PTSD. Their future depends on the results of clinical trials. This timeline is unrelated to their mission to create new medications for mental health.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772610973215 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bionomics Limited
Bionomics is a clinical-stage biotech company developing drugs for the treatment of anxiety disorders and PTSD. It has no sales revenue. Its financial history is based on investments in science. The graph will reflect future revenue from licensing or partnerships for its drug candidates following successful trials.
Sales of companies in the market segment - Pharma neurology
Bionomics Limited is an Australian clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. It currently has no sales revenue. Its future revenue depends on the success of its lead candidate for the treatment of anxiety disorders.
Overall market sales
Bionomics Limited is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. Its success depends on the results of clinical trials. Demand for such drugs is enormous, but the overall economic situation, shown in this chart, affects the funding available for mental health R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bionomics Limited
Bionomics is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. This chart reflects long-term expectations for its clinical programs.
%20sales%20of%20the%20company%20Bionomics%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bionomics-Limited&v=1772610973392 "Schedule of future (projected) sales of the company Bionomics Limited")
Future (projected) sales of companies in the market segment - Pharma neurology
Bionomics Limited is a biopharmaceutical company developing drugs for the treatment of anxiety and other central nervous system disorders. This chart shows the outlook for the neurological pharmaceutical sector. It reflects the urgent need for new, more effective, and safer treatments for mental illnesses.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772610973432 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines the prospects for Bionomics. The biotech company develops drugs for the treatment of central nervous system diseases. Funding for its research depends on capital inflows, which increase with favorable forecasts.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772610973479 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bionomics Limited
Bionomics is a clinical-stage biotechnology company focused on developing drugs for the treatment of central nervous system disorders, such as anxiety disorders. This chart reflects its R&D investments. Future profitability depends on the success of clinical trials and the commercialization of its lead candidate.
Market segment marginality - Pharma neurology
Bionomics is an Australian biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders and post-traumatic stress disorder. Profitability depends on the success of its clinical programs. This chart shows the average profitability in the pharmaceutical industry, providing context for evaluating its developments.
Market marginality as a whole
Bionomics is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its future depends on the success of clinical trials, particularly its lead candidate. This chart reflects the overall risk appetite of investors, which is critical for raising the capital needed to complete expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Bionomics Limited
Bionomics Limited is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders. This graph shows a compact scientific team. Growth will indicate progress in late-stage clinical trials, which will require expansion of the team to prepare for market entry.
Share of the company's employees Bionomics Limited within the market segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs to treat central nervous system disorders such as anxiety and PTSD. This chart shows the company's share of the total number of neuroscientists working in this field, reflecting its scientific focus on complex mental illnesses.
Number of employees in the market segment - Pharma neurology
Bionomics Limited is a biopharmaceutical company developing new drugs for the treatment of central nervous system disorders, such as anxiety and post-traumatic stress disorder. This chart, showing employment in the neurological pharmaceutical sector, is important. The growing number of neuroscientists indicates a high demand for more effective and safer treatments.
Number of employees in the market as a whole
Bionomics develops drugs to treat anxiety disorders and PTSD. This overall employment growth chart reflects the growing attention of society and employers to mental health. A stable economy allows companies to invest in employee support programs, and healthcare systems to develop new, more effective treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bionomics Limited (BNOX)
Bionomics (BNOX) is an Australian biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders (anxiety, PTSD). This is a classic R&D business. The company's market value is a bet on the success of their clinical trials. This chart reflects the high valuation of their "intellectual capital."
%20of%20the%20company%20Bionomics%20Limited%20(BNOX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bionomics-Limited-BNOX&v=1772610973815 "Chart of market capitalization per employee (in thousands of dollars) of the company Bionomics Limited (BNOX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Bionomics is a biotech company developing drugs to treat central nervous system disorders such as anxiety and PTSD. Its value is determined by progress in clinical trials. This chart helps understand how the market values the company's scientific potential based on its small but highly specialized research team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772610973842 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Bionomics is a clinical-stage biopharmaceutical company developing drugs for the treatment of anxiety disorders and PTSD. Market value in this field depends on the success of clinical trials. This chart illustrates how a small, focused team can generate enormous market value by addressing serious mental health challenges.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772610973845 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bionomics Limited (BNOX)
Bionomics is an Australian biotech company developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders and PTSD. This is R&D. This chart shows the company's "burn rate": how much the company spends (negative profit) on each scientist to conduct clinical trials of these complex drugs.
%20Chart%20Bionomics%20Limited%20(BNOX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bionomics-Limited-BNOX&v=1772610973850 "Company Profit Per Employee (in thousands of dollars) Chart Bionomics Limited (BNOX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Bionomics is a biotech company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. The company incurs significant expenses during clinical trials. This chart helps evaluate the effectiveness of capital management on the path to developing marketable drugs.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772610973912 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Bionomics (BNOX) is an Australian biopharmaceutical company developing drugs for the treatment of central nervous system disorders (anxiety, PTSD). It is a clinical-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of neuroscience.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772610974040 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bionomics Limited (BNOX)
Bionomics Limited is an Australian biopharmaceutical company developing drugs for the treatment of central nervous system disorders. While in the clinical stage, it may not generate significant revenue. This chart is used to estimate the future potential of their drugs if successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bionomics-Limited-BNOX&v=1772610974131 "Sales chart per company employee Bionomics Limited (BNOX)")
Sales per employee in the market segment - Pharma neurology
Bionomics is an Australian clinical-stage biotech company focused on treating CNS disorders (anxiety, PTSD). It's an R&D company. This chart reflects their clinical stage. Their research team's productivity lies in developing and advancing drug candidates, not in ongoing sales.
Sales per employee for the market as a whole
Atlanticus Holdings (ATLC) is a fintech company specializing in second-look lending for consumers who have been denied traditional credit. They operate through retailers and direct channels. This chart shows the effectiveness of their fintech platform. Atlanticus' success depends on their ability to quickly (and accurately) assess risks using AI and automate loan servicing, allowing them to scale their portfolio.
Short shares by company, segment and market as a whole
Shares shorted by company Bionomics Limited (BNOX)
Bionomics (BNOX) is an Australian biotech company developing drugs for the treatment of PTSD and anxiety. This chart tracks bearish bets. Shorts reflect a high risk of failure in clinical trials of CNS drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bionomics-Limited-BNOX&v=1772610974239 "Short Shares Chart for the Company Bionomics Limited (BNOX)")
Shares shorted by market segment - Pharma neurology
Bionomics (BNOX) is an Australian biotech developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders. The chart below shows the overall short position in the CNS biotech sector. It demonstrates the investor distrust in the success of complex and lengthy clinical trials.
Shares shorted by the overall market
Bionomics is an Australian biotech company working on complex CNS disorders (anxiety, PTSD). This chart illustrates the overall market pessimism. When fear mounts, investors are unwilling to fund "long-term science." They see the R&D costs and fear running out of money before they see results.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bionomics Limited (BNOX)
Bionomics (BNOX) is an Australian biotech company developing drugs to treat anxiety disorders and PTSD. The need for such drugs is enormous. This chart measures the rate of price change. It helps identify when enthusiasm (above 70) about trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bionomics-Limited-BNOX&v=1772610974333 "RSI 14 indicator chart for the company's stock Bionomics Limited (BNOX)")
RSI 14 Market Segment - Pharma neurology
Bionomics is an Australian biotech company developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders and post-traumatic stress disorder (PTSD). This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Bionomics, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BNOX (Bionomics Limited)
Bionomics is an Australian biotech company developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders and PTSD. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of clinical trials in this complex area.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BNOX-Bionomics-Limited&v=1772610974417 "A chart showing analyst consensus forecasts for the expected stock price. BNOX (Bionomics Limited)")
The difference between the consensus estimate and the actual stock price BNOX (Bionomics Limited)
Bionomics (BNOX) is an Australian biotech company developing drugs to treat severe CNS disorders, particularly PTSD and anxiety disorders. This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see in their R&D portfolio for these massive markets.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BNOX-Bionomics-Limited&v=1772610974446 "A chart showing the difference between the consensus forecast and the actual stock price. BNOX (Bionomics Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Bionomics (BNOX) is an Australian biotech company developing drugs (BNC210) for the treatment of anxiety disorders and PTSD. This is high-risk R&D. This chart shows the overall expectations of analysts in the neuroscience sector. It reflects whether experts believe a breakthrough in the treatment of mental disorders is possible.
Analysts' consensus forecast for the overall market share price
Bionomics (BNOX) is an Australian clinical-stage biopharmaceutical company focused on treating brain diseases, primarily anxiety disorders and PTSD. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bionomics Limited
Bionomics is an Australian biotech R&D company focused on the brain. Their R&D pipeline (inhibitors) is aimed at novel treatments for anxiety (GAD) and PTSD. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline, their clinical trial data, and their partnerships (Merck).
AKIMA Market Segment Index - Pharma neurology
Bionomics is an Australian biopharmaceutical company focused on the brain. They are developing new drugs for the treatment of anxiety disorders and PTSD, a complex area of neuroscience. This chart compares their composite index to the sector, showing how their approach to brain pharma compares to others.
The AKIM Index for the overall market
Bionomics is an Australian biopharmaceutical company developing treatments for anxiety disorders and PTSD. This chart, which reflects the market average, provides a macro backdrop. It helps assess how BNOX, a scientific story in psychiatry, compares to overall economic trends.
